Talphera (TLPH) Other Non-Current Assets (2010 - 2023)
Talphera (TLPH) posted Other Non-Current Assets of $20000.0 for Q4 2023, little changed on a QoQ basis from $20000.0 in Q3 2023, and down 99.86% year-over-year from $13.9 million in Q4 2022.
Analysis
Talphera (TLPH) Other Non-Current Assets (2010 - 2023) Analysis & Trends
Talphera has reported Other Non-Current Assets for 14 years, with the latest figure at $20000.0 in Q4 2023.
- On a quarterly basis, Other Non-Current Assets fell 99.86% year-over-year to $20000.0 in Q4 2023; TTM through Dec 2023 was $20000.0, a 99.86% decrease from a year earlier, with the FY2023 full-year figure at $20000.0, down 99.86% from the prior year.
- Other Non-Current Assets was $20000.0 for Q4 2023 at Talphera, roughly flat from $20000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $13.9 million in Q4 2022, with the low at $20000.0 in Q3 2023.
- Average Other Non-Current Assets over 5 years is $2.2 million, with a median of $901000.0 recorded in 2019.
- The largest YoY upside for Other Non-Current Assets was 1231.8% in 2023 against a maximum downside of 99.86% in 2023.
- Over 5 years, Other Non-Current Assets stood at $1.2 million in 2019, then surged by 320.88% to $5.0 million in 2020, then changed by 0.0% to $5.0 million in 2021, then jumped by 178.72% to $13.9 million in 2022, then tumbled by 99.86% to $20000.0 in 2023.
- The last three Other Non-Current Assets figures came in at $20000.0 (Q4 2023), $20000.0 (Q3 2023), and $70000.0 (Q2 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | 13.94 Mn |
| Sep 30, 2022 | 251,000.00 |
| Jun 30, 2022 | 257,000.00 |
| Mar 31, 2022 | 261,000.00 |
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 5.00 Mn |
| Jun 30, 2021 | 5.00 Mn |
| Mar 31, 2021 | 70,000.00 |
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | 720,000.00 |
| Jun 30, 2020 | 784,000.00 |
| Mar 31, 2020 | 902,000.00 |
| Dec 31, 2019 | 1.19 Mn |
| Sep 30, 2019 | 984,000.00 |
| Jun 30, 2019 | 1.02 Mn |
| Mar 31, 2019 | 900,000.00 |